Chronic inhibition of LRRK2 as a therapeutic target in PD: how safe will it be in humans?
We are excited to share the publication of our latest research that explored the molecular effects of long-term pharmacological LRRK2 inhibition in vivo. This comprehensive study was completed by Ph.D. candidate Jillian H. Kluss in the lab of Dr. Mark R. Cookson at the National Institute on Aging, NIH.
